Research programme: infectious disease and cancer therapies - Entomed/NAEJA Pharmaceuticals
Latest Information Update: 25 Oct 2007
At a glance
- Originator Entomed; NAEJA Pharmaceutical
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Bacterial infections; Cancer
Most Recent Events
- 25 Oct 2007 Discontinued - Preclinical for Bacterial infections in Canada (unspecified route)
- 25 Oct 2007 Discontinued - Preclinical for Bacterial infections in France (unspecified route)
- 25 Oct 2007 Discontinued - Preclinical for Cancer in Canada (unspecified route)